• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Revance Therapeutics, Inc. (RVNC)

    -NasdaqGM
    16.79 Up 0.14(0.84%) Dec 26, 4:00PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingSep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013
    Total Revenue 75   75   158   309  
    Cost of Revenue -   -   -   -  
    Gross Profit 75   75   158   309  
    Operating Expenses
    Research Development8,600  8,110  7,551  6,239  
    Selling General and Administrative5,300  4,857  4,093  3,003  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (13,825) (12,892) (11,486) (8,933)
    Income from Continuing Operations
    Total Other Income/Expenses Net76  (143)(99)552  
    Earnings Before Interest And Taxes(13,749)(13,035)(11,585)(8,381)
    Interest Expense228  267  9,841  1,698  
    Income Before Tax(13,977)(13,302)(21,426)(10,079)
    Income Tax Expense -   -   -   -  
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(13,977)(13,302)(21,426)(10,079)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (13,977) (13,302) (21,426) (10,079)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (13,977) (13,302) (21,426) (10,079)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.